Also trades as: CYTHW (NASDAQ) · $vol 0M
CYTH NASDAQ
Cyclo Therapeutics, Inc.
1W: +6.0%
1M: -6.3%
3M: +19.7%
1Y: -49.6%
3Y: -75.7%
5Y: -96.0%
$0.72
Last traded 2025-03-27 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$1M
-21.8% ▼
5Y CAGR: +1.3%
Gross Profit
$978K
-20.9% ▼
5Y CAGR: +1.5%
Operating Income
-$20M
-28.4% ▼
Net Income
-$20M
-31.3% ▼
EPS (Diluted)
$-1.23
+32.0% ▲
EBITDA
-$20M
-28.4% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $1M | $903K | $2M | $1M | $1M |
| YoY Growth | -0.4% | -10.3% | +75.5% | -13.2% | -21.8% |
| Cost of Revenue | $75K | $66K | $156K | $139K | $98K |
| Gross Profit | $932K | $837K | $1M | $1M | $978K |
| Gross Margin | 92.5% | 92.7% | 90.2% | 89.9% | 90.9% |
| R&D Expenses | $5M | $6M | $9M | $9M | $14M |
| SG&A Expenses | $3M | $4M | $7M | $8M | $6M |
| Operating Expenses | $8M | $10M | $16M | $17M | $21M |
| Operating Income | -$7M | -$9M | -$14M | -$16M | -$20M |
| Operating Margin | -733.8% | -991.8% | -899.8% | -1134.8% | -1862.7% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$8M | -$9M | -$14M | -$15M | -$20M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$8M | -$9M | -$14M | -$15M | -$20M |
| Net Margin | -761.9% | -987.7% | -902.1% | -1110.7% | -1863.4% |
| EPS (Diluted) | $-7.09 | $-5.58 | $-2.25 | $-1.81 | $-1.23 |
| EBITDA | -$7M | -$9M | -$14M | -$16M | -$20M |
| Shares Outstanding | 1M | 2M | 6M | 8M | 16M |